Inhaled nitric oxide therapy in premature newborns

Kinsella, John P.

doi:10.1097/01.mop.0000193291.09894.6c

Cited by 19 publications

(5 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Breathing low concentrations of NO gas reduces pulmonary arterial pressures without producing systemic hypotension in animal models and children [ 14 , 15 ], and inhaled NO has been safely used to treat persistent pulmonary hypertension and other pulmonary disorders [ 16 , 17 ] in neonates and infants for over 20 years [ 18 ]. In Plasmodium berghei ANKA (PbA)-infected mice (a murine CM model), breathing 40 or 80 parts per million (ppm) of inhaled NO [ 19 , 20 ] improved survival rates, reduced plasma inflammatory markers, and increased plasma Ang-1 levels.…”

mentioning

confidence: 99%

Inhaled Nitric Oxide as an Adjunctive Treatment for Cerebral Malaria in Children: A Phase II Randomized Open-Label Clinical Trial

Mwanga-Amumpaire

Carroll

Baudin³

et al. 2015

Open Forum Infectious Diseases

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

Inhaled Nitric Oxide as an Adjunctive Treatment for Cerebral Malaria in Children: A Phase II Randomized Open-Label Clinical Trial

Mwanga-Amumpaire

Carroll

Baudin³

et al. 2015

Open Forum Infectious Diseases

View full text Add to dashboard Cite

show abstract

“…Although studies in newborns and infants suggest that inhaled NO is safe [32,33], the long-term pulmonary and extrapulmonary effects of inhaled NO are unknown. In particular, the effects of chronic NO inhalation on normal pulmonary cell proliferation and differentiation, as well as on alveolar and microvascular development, are unknown.…”

Section: Safety Of Inhaled No In the Newbornmentioning

confidence: 98%

Inhaled NO as a therapeutic agent

Bloch

Ichinose

Roberts

et al. 2007

Cardiovascular Research

142

101

View full text Add to dashboard Cite

In 1991, Frostell and colleagues reported that breathing low concentrations of nitric oxide (NO) decreased pulmonary artery pressure (PAP) in awake lambs with experimental pulmonary hypertension (PH) [Frostell C, Fratacci MD, Wain JC, Jones R, Zapol WM. Inhaled nitric oxide. A selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction. Circulation 1991;83:2038-47]. Subsequently, efforts of multiple research groups studying animals and patients led to approval of inhaled NO by the US Food and Drug Administration in 1999 and the European Medicine Evaluation Agency and European Commission in 2001. Inhaled NO is currently indicated for the treatment of term and near-term neonates with hypoxemia and PH. Since regulatory approval, several studies have suggested that NO inhalation can prevent chronic lung disease in premature infants. In addition, unanticipated systemic effects of inhaled NO may lead to treatments for a variety of disorders including ischemia-reperfusion injury. This review summarizes the pharmacology and physiological effects of breathing NO. The application of inhaled NO to hypoxemic neonates with PH is discussed including recent studies exploring the use of inhaled NO to prevent bronchopulmonary dysplasia in premature infants. This review also highlights the application of inhaled NO to treat adults with cardiopulmonary disease, strategies to augment the efficacy of inhaled NO, and potential applications of the systemic effects of the gas.

show abstract

“…Although long-term inhaled NO treatment has been used in the BPD patients, especially those who require continuous mechanical ventilation, no study has reported such data to date. Preventive low-dose inhaled NO supply can reduce the incidence of BPD in the preterm infants with birth weight greater than 1,000 g, but it showed no effect in the infants with birth weight less than 1,000 g. Therefore, the use of preventive inhaled NO for BPD prevention is questionable30, 31). Most patients require an initial inhaled NO dose of 10-20 parts per million (ppm) for PH treatment and a maintenance dose of 2-10 ppm for weaning.…”

Section: Treatment Of Ph In the Bpd Patientsmentioning

confidence: 99%

Pulmonary hypertension in infants with bronchopulmonary dysplasia

Kim

2010

Korean J Pediatr

View full text Add to dashboard Cite

An increase in the number of preterm infants and a decrease in the gestational age at birth have resulted in an increase in the number of patients with significant bronchopulmonary dysplasia (BPD) and secondary pulmonary hypertension (PH). PH contributes significantly to the high morbidity and mortality in the BPD patients. Therefore, regular monitoring for PH by using echocardiography and B-type natriuretic peptide (BNP) or N-terminal-proBNP must be conducted in the BPD patients with greater than moderate degree to prevent PH and to ensure early treatment if PH is present. In the BPD patients with significant PH, multi-modality treatment, including treatment for correcting an underlying disease, oxygen supply, use of diverse selective pulmonary vasodilators (inhaled nitric oxide, inhaled prostacyclins, sildenafil, and endothelin-receptor antagonist) and other methods, is mandatory.

show abstract

Inhaled nitric oxide therapy in premature newborns

Cited by 19 publications

References 41 publications

Inhaled Nitric Oxide as an Adjunctive Treatment for Cerebral Malaria in Children: A Phase II Randomized Open-Label Clinical Trial

Inhaled Nitric Oxide as an Adjunctive Treatment for Cerebral Malaria in Children: A Phase II Randomized Open-Label Clinical Trial

Inhaled NO as a therapeutic agent

Pulmonary hypertension in infants with bronchopulmonary dysplasia

Contact Info

Product

Resources

About